# Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

> **NCT03309878** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 8 (actual)

## Conditions studied

- Recurrent Diffuse Large B-Cell Lymphoma
- Recurrent High Grade B-Cell Lymphoma
- Recurrent Transformed B-Cell Non-Hodgkin Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Refractory High Grade B-Cell Lymphoma
- Refractory Transformed B-Cell Non-Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** Mogamulizumab
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03309878
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-24
- **Primary completion:** 2021-01-06
- **Final completion:** 2023-04-11
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2023-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03309878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03309878, "Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03309878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*